LEO Pharma recieves scientific approval of Enstilar® for the treatment of psoriasis in EU

The marketing approval of Enstilar® would make it the first fixed combination topical foam treatment for people living with psoriasis vulgaris in the EU

Source: Pharmacy Europe - March 21, 2016 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Legislation & regulation Dermatology Patient care calcipotriol/betamethasone dipropionate enstilar fixed combination topical foam Latest News psoriasis vulgaris Source Type: news